Abstract: Provided are an anticancer agent, radiosensitizer, and food composition capable of enhancing the effects of radiation therapy. The present inventors discovered that tumors shrink significantly in comparison to an untreated group and the respective monotherapy groups when treatment by burdock fruit extract containing arctigenin and radiation therapy were used in combination on mice transplanted with human pancreatic cancer cells. The anticancer agent of the present invention is an anticancer agent containing arctigenin and/or arctiin as the active ingredient, to be used in combination with radiation therapy. The arctigenin and/or arctiin may be contained as burdock, burdock fruit, burdock sprout, or forsythia, or an extract extracted from these.

Abstract: The present invention relates to an anticancer T cell therapy product-assisting composition comprising a depleting anti-CD4 monoclonal antibody and a use thereof. Accordingly, the composition comprising a depleting anti-CD4 monoclonal antibody according to the present invention is able to maximize the anticancer effect of a cancer antigen-specific anticancer T cell therapy product by maintaining an immunodeficient state and is thus effective. In addition, when administered twice or more times at regular intervals of 5 to 8 days, the composition exhibits a far superior effect.

Abstract: The present invention provides an epidermal penetration type ink composition comprising: a fluorescent colorant containing at least one selected from the group consisting of indocyanine green (ICG), cyanine, phthalocyanine, oxazine, rhodamine, and a mixture thereof; a binder resin containing at least one of polyvinylpyrrolidone (PVP) and polyvinylbutyral (PVB); and a solvent containing at least one of ethanol and isopropanol.

Abstract: The present invention relates to a device of diagnosing a colorectal cancer and a method for providing colorectal cancer diagnosis information. A colorectal cancer diagnosing device according to the present invention includes: an input unit which acquires mass spectrometry data measured from a biological sample; a concentration detecting unit which measures a concentration of nudifloramide from the acquired mass spectrometry data; and a diagnosing unit which determines diagnosis information of the colorectal cancer based on a measurement result of the concentration detecting unit.

Abstract: This application provides a kit or a device for detection of ovarian tumor, comprising a nucleic acid(s) for detecting a miRNA(s) in a sample from a subject, and a method for detecting ovarian tumor, comprising measuring the miRNA(s) in vitro.

Abstract: The present invention provides a skull implant-type automatic fluid drain device comprising: a body having a first port to be connected to a catheter, a second port provided opposite the first port, and a flow passage connecting the first port and the second port; a separation member for separating the flow passage into first and second sub-channels; a first valve fixed to the separation member and provided to allow the movement of a fluid that moves from the first port to the second port in the first sub-channel; and a second valve fixed to the separation member and provided to allow the movement of a fluid that moves from the second port to the first port in the second sub-channel, wherein each of the first valve and the second valve has an inflow end portion that is open and a discharge end portion provided in a closed state such that the same is selectively opened at an allowed opening pressure or higher; each of the first valve and the second valve is configured such that the inner flow sectional area de

Abstract: A method for evaluating an efficacy of a chemoradiotherapy against squamous cell carcinoma comprises the following steps (a) to (c): (a) detecting an expression level of at least one gene selected from a SIM2 gene and genes co-expressed with the SIM2 gene in a squamous cell carcinoma specimen isolated from a subject; (b) comparing the expression level detected in the step (a) with a reference expression level of the corresponding gene; and (c) determining that an efficacy of a chemoradiotherapy against squamous cell carcinoma in the subject is high if the expression level in the subject is higher than the reference expression level as a result of the comparison in the step (b).

Abstract: The present invention relates to a method, a device, and a program for calculating a brachytherapy plan, and a brachytherapy apparatus. The method comprises: a step in which a computer obtains the number of radiation irradiation spots on the basis of radiation irradiation information (a radiation irradiation spot number obtaining step (S200)); a step in which the computer obtains target area information from a body model of a patient generated on the basis of medical image data of the patient (a target area information obtaining step (S400)); and a therapy plan calculating step (S600) in which the computer calculates, on the basis of the radiation irradiation information and the target area information, the radiation irradiation spots to which radiation is irradiated and the time length of irradiation to each radiation irradiation spot.

Abstract: The present invention relates to a stemness-suppressing composition comprising an OCT4 function-inhibiting peptide and, more particularly, to a composition comprising a peptide as an effective ingredient for suppressing the stemness of various stem cells such as general stem cells, cancer stem cells, and the like, wherein the peptide inhibits the function of OCT4 by inducing the phosphorylation of OCT4. OCT4 function-inhibiting peptides of the present invention are expected to find applications in various fields through the suppressive activity thereof against stemness of stem cells.

Abstract: Provided is a non-transitory computer-readable storage medium storing a program causing a computer to execute a process, the process including: receiving a first operation that specifies a person symbol from a plurality of person symbols representing persons present in a family tree; displaying a plurality of first candidate person symbols capable of being connected with the person symbol specified by the received first operation by referring to a first storage unit that stores attribute information with respect to each of a plurality of persons; receiving a second operation that selects a first candidate person symbol from the plurality of first candidate person symbols that have been displayed; and displaying the first candidate person symbol selected by the received second operation while the selected first candidate person symbol is being connected with the person symbol specified by the first operation.

Abstract: This invention provides a kit or a device for the detection of pancreatic cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, comprising measuring the miRNA(s) in vitro.

Abstract: An information processing apparatus (2000) extracts a histomorphological feature of a tissue included in pathological image data (10). The information processing apparatus (2000) generates prediction data (30) based on the extracted histomorphological feature. The prediction data (30) indicates one or more of a prediction relating to an effect of a cancer therapeutic drug on a target patient and a prediction of a side effect of the cancer therapeutic drug on the target patient.

Abstract: The present disclosure concerns a medical image indicator. More particularly, it concerns the multipurpose medical image indicator including more than one of fluorophores and MRI contrast agent/CT contrast agent and method for manufacturing same. Responding to a demand for non-invasive and effective way of marking lesions, the present disclosure provides a method for manufacturing the multipurpose medical image indicator including a provision of rubber material fluid composition; a mixing of the rubber material fluid composition and fluorophores; and a transfiguring and drying of the mixture and the multipurpose medical image indicator manufactured according to the method. Further, the present disclosure provides a ligation device for endoscope including the multipurpose medical image indicator.

Abstract: Disclosed is a genome stability enhancer comprising, as an active ingredient, at least one member selected from the group consisting of enzyme-treated royal jelly, gnetum or its extract, and gnetin C.

Abstract: The present invention relates to a sentinel lymph node marker comprising an albumin; a radioactive isotope and/or near infrared dye which is bound to the albumin; and a visible dye which is bound to the albumin, a preparation method thereof, and a kit for multimode imaging of a sentinel lymph node to prepare the sentinel lymph node marker. The sentinel lymph node marker of the invention remains in the sentinel lymph node for a long period of time and allows for multimode imaging of the sentinel lymph node. Thus, using this marker the sentinel lymph node can be accurately identified in vivo by near infrared imaging and/or gamma imaging without incision of skin, and the location of the identified sentinel lymph node can be precisely identified with the naked eye during a surgical operation of removing the identified sentinel lymph node.

Abstract: Provided are biomarkers that are sensitive or resistant to poziotinib therapy for cancer and methods of using the biomarkers.

Abstract: Provided is a method for isolating and proliferating autologous cancer antigen-specific CD8+T cells, and more particularly, a method for selecting an epitope recognized by CD8+ T cells from autologous cancer antigens present in blood of individual cancer patients; and isolating autologous cancer antigen-specific CD8+ T cells by using a peptide of the selected epitope, and a method of massively proliferating CD8+ T cells by using the method. According to the present invention, it is possible to isolate autologous cancer antigen-specific CD8+ T cells by using the peptide of the CD8 T cell epitope of the autologous cancer antigen present in blood of individual cancer patients instead of a heterologous antigen. Therefore, by using T cells recognizing the autologous cancer antigen, it is possible to effectively select and eliminate cancer cells derived from the cancer patient's own cells. Thus, T cells can be applied to treatment and alleviation of cancer diseases without side effects.

Abstract: It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample f a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.

Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

Abstract: It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.